APOBEC3B as a Biomarker and Therapeutic Vulnerability in TP53-aberrant Multiple Myeloma

Funding Cycle:

2026-2027

Name:

Afsaneh Panahi

Type of Award:

Career Development Award

Home Institution:

BC Cancer

Host Institution:

Dana-Farber Cancer Institute

Description

This project investigates APOBEC3B (A3B) as a biomarker and therapeutic vulnerability in high-risk multiple myeloma with TP53 aberrations. Through the integration of patient-derived datasets, genetically engineered model systems, and primary patient samples, the study aims to define biologically aggressive A3B-high disease states and uncover targetable stress-response dependencies that may inform more precise treatment strategies for patients with high-risk TP53-aberrant multiple myeloma.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events

  • This field is for validation purposes and should be left unchanged.